Organisation: Avonex

Sign in

Organisation: Avonex

A COMPREHENSIVE SERIES OF ARTICLES ON THIS TOPIC

business

Elan in talks to settle death claim

ELAN is to enter into talks to settle a lawsuit taken against the company by the family of a woman who died after taking its multiple sclerosis drug Tysabri.

business

Elan receives notification of Tysabri review

business

Elan and Biogen hoping to relaunch MS drug

business

ISEQ sees 95-point boost

business

Financials and Elan boost ISEQ

business

ISEQ up as Elan makes gains

Elan jump sets positive tone on ISEQ

Shares in pharmaceutical company Elan jumped 35c to €3.30 today, on the back of some good news from the States.

Wed, 13 Apr, 2005

Neurology conference presents positive news for Elan

There was good news for embattled Athlone-based pharmaceutical company Elan overnight after data presented at a neurology conference showed treatment with under-fire multiple sclerosis (MS) drug Tysabri led to a significant reduction in progression of the disease.

Wed, 13 Apr, 2005

Only way is down for Elan

Elan chief executive Kelly Martin’s contract includes $5m if Elan is sold this year and $3m if it goes next year, adding to doubts about the company’s survival after the announcement of a third patient death. BRIAN O'MAHONY reports.

Sat, 02 Apr, 2005

Devastating news for Elan as third Tysabri patient death confirmed

There has been devastating news for Athlone-based pharmaceutical company Elan overnight after a safety evaluation of the drug Tysabri led to the revelation that a third patient using the drug had died.

Thu, 31 Mar, 2005

MS Society disappointed over Elan drug deaths

The head of the Multiple Sclerosis Society of Ireland has described news that a second patient being treated with the new MS drug, Tysabri, has developed a rare neurological virus as "very disappointing".

Sat, 05 Mar, 2005

Elan hammered by second death

SHARES in Irish drug company Elan were hammered again in Dublin yesterday as news of a second death linked to its multiple sclerosis drug, Tysabri, hit the market.

Sat, 05 Mar, 2005

Elan shares in freefall after second death

Elan shares plummeted 67c to €4.90 as the ISEQ opened this morning, after news of a second confirmed death of a patient being treated on the company's multiple sclerosis drug Tysabri.

Fri, 04 Mar, 2005

€5.4bn wiped off Elan shares

ELAN had €5.4 billion wiped off its share value yesterday as shareholders saw the value of their investments fall by 68.62%.

Tue, 01 Mar, 2005

MS drug withdrawn after patient dies

IRISH drugs group Elan and its partner Biogen have withdrawn sales of its multiple sclerosis drugs after a patient died from the rare and often fatal central nervous system disease, sending shares of both drug makers tumbling.

Tue, 01 Mar, 2005

Market dives as Elan drug withdrawn

THE Irish market tumbled yesterday as Elan announced the suspension of Tysabri. The index dropped 387.40 points to finish at 6271.62.

Tue, 01 Mar, 2005